Atlas Trials

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Clinical trial NCT03863483 · UNKNOWN

Trial details

NCT number
NCT03863483
Sponsor
Xin-Hua Xu
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Nonsquamous Non-Small Cell Lung Cancer
Start date
2019-03-26
Primary completion
2021-12-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.